Recent studies have centered on the intersection of GLP-1|GIP|GCGR activator therapies and DA signaling. While GCGR agonists are widely employed for treating type 2 diabetes, their emerging impacts on reward circuits, https://caraqrte756869.mpeblog.com/75230779/novel-gip-stimulators-and-dopaminergic-influence-a-contextual-overview